Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psilocybin Oral Solution in Generalized Anxiety Disorder
NCT06969170Phase 2Recruiting
- Sponsor
- Claudio N Soares
- Start
- May 2025
- Primary completion
- Dec 2027
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in generalized anxiety disorder (GAD) comparing Psilocybin Oral Solution with Placebo (2 arms). Primary endpoint: Safety and tolerability of psilocybin at 14 weeks. Started May 2025; status: recruiting.
02
Drugs
psilocybin
03
Conditions
generalized anxiety disorder (GAD)
Beyond the preview
Go deeper on NCT06969170.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06969170.